Monthly Archives: September, 2010
BIOD Downgrade to Market Perform
Leerink Swann downgrades Biodel, Inc. (Nasdaq: BIOD) from Outperform to Market Perform. Leerink analyst says, “The PDUFA date for BIOD’s Linjeta is Oct. 30, 2010, and shares have appreciated nearly 40% over the past three months as this event draws near. We are moving to the sidelines pending visibility on the FDA decision. We believe [...]
IDIX Conference call today at 8:30 am ET
Conference call today at 8:30 am ET
Idenix Provides Update on HCV Clinical Development Activities
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical [...]
Idenix Pharma (IDIX) Receives Clinical Hold from U.S. FDA for IDX184 and IDX320 Programs
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) receives notice from the U.S. FDA that a clinical hold has been placed on IDX184 and IDX320 programs. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. The hold was put on after Idenix [...]
Inhibitex Successfully Completes Phase 1a Trial of INX-189
Inhibitex, Inc. (Nasdaq:INHX – News)announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 [...]